19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Q fever seroprevalence in parturient women: the EQRUN cross-sectional study on Reunion Island

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Q fever ( Coxiella burnetii infection) has been associated with adverse perinatal outcomes. After investigating the obstetrical importance of Q fever on Reunion island and demonstrating an association between incident Q fever and miscarriage, we conducted a cross-sectional serosurvey to assess the prevalence of Coxiella burnetii infection among parturient women.

          Methods

          Between January 9 and July 24, 2014, within the level-4 maternity of Saint Pierre hospital and the level-1 maternity of Le Tampon, we proposed to screen all parturient women for Coxiella burnetii serology. Seropositivity was defined using indirect immunofluorescence for a dilution of phase 2 IgG titre ≥1:64. Further dilutions were chosen to discriminate recent or active infections from past or prevalent infections (< 1:128) and classify these as either possible (1:128), or probable (≥1:256). Recurrent miscarriage, stillbirth, preterm birth, small-for-gestational as well as a composite outcome of these adverse pregnancy outcomes were compared according to seropositivity using bivariate analysis or propensity score matching of seropositive and seronegative women on confounding factors.

          Results

          Among 1112 parturient women screened for Q fever over this 7-month period, 203 (18.3%) were seropositive. Overall weighted seroprevalence was of 20.1% (95%CI, 17.7–22.5%). Weighted seroprevalence of probable infections was 4.7% (95%CI 3.4–5.9%), while > 90% of positive serologies corresponded to past infections or false positives. Seropositivity was associated with none of the abovementioned adverse perinatal outcomes, whether in unpaired or matched analyses on propensity score.

          Conclusion

          The magnitude and the pattern of seroprevalence suggest that Q fever is endemic on Reunion island. In this context, we found no significant contribution of prevalent Coxiella burnetii infection to adverse pregnancy outcomes. Although reassuring, these data put in our endemic context, with a previously demonstrated increased risk of incident Q fever associated miscarriage, encourage us to protect pregnant women against the risk of new infection, periconceptional or early in pregnancy.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Q fever.

          Q fever is a zoonosis with many manifestations. The most common clinical presentation is an influenza-like illness with varying degrees of pneumonia and hepatitis. Although acute disease is usually self-limiting, people do occasionally die from this condition. Endocarditis is the most frequent chronic presentation. Although Q fever is widespread, practitioner awareness and clinical manifestations vary from region to region. Geographically limited studies suggest that chronic fatigue syndrome and cardiovascular disease are long-term sequelae. An effective whole-cell vaccine is licensed in Australia. Live and acellular vaccines have also been studied, but are not currently licensed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Q fever serology: cutoff determination for microimmunofluorescence.

            Q fever, a worldwide zoonosis caused by Coxiella burnetii, lacks clinical specificity and may present as acute or chronic disease. Because of this polymorphism, serological confirmation is necessary to assess the diagnosis. Although microimmunofluorescence is our reference technique, the cutoff titers that are currently used to make a diagnosis of active or chronic Q fever were determined years ago with limited series of patients and sera. We determined the titers of immunoglobulin G (IgG), IgM, and IgA against both phases (I and II) of Coxiella burnetii. Rheumatoid factor was removed before testing IgM and IgA. We report here the various cutoff titers and the kinetics of antibody development from 2,218 first serum samples of patients, among whom 208 suffered from acute Q fever and 53 had chronic Q fever. In active Q fever, we have defined a low cutoff (phase II IgG titer or = 200 and phase II IgM titer > or = 50) over which the diagnosis can be made. For chronic Q fever diagnosis, phase I IgA titers are not contributive despite previous works claiming their usefulness; a phase I IgG titer of > or = 800 is highly predictive (98%) and sensitive (100%). We have also studied the possibility of rejecting or evoking the diagnosis of chronic Q fever by phase II IgG and IgA titers. This method is useful when phase I testing is not available, but the sensitivity remains low (57%).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Maternal-fetal transmission and adverse perinatal outcomes in pregnant women infected with Zika virus: prospective cohort study in French Guiana

              Abstract Objectives To estimate the rates of maternal-fetal transmission of Zika virus, adverse fetal/neonatal outcomes, and subsequent rates of asymptomatic/symptomatic congenital Zika virus infections up to the first week of life. Design Cohort study with prospective data collection and subsequent review of fetal/neonatal outcomes. Settings Referral centre for prenatal diagnosis of the French Guiana Western Hospital. Participants Pregnant women at any stage of pregnancy with a laboratory confirmed symptomatic or asymptomatic Zika virus infection during the epidemic period in western French Guiana. The cohort enrolled 300 participants and prospectively followed their 305 fetuses/newborns. Main outcome measures Rate of maternal-fetal transmission of Zika virus (amniotic fluid, fetal and neonatal blood, urine, cerebrospinal fluid, and placentas); clinical, biological, and radiological outcomes (blindly reviewed); and adverse outcomes defined as moderate signs potentially related to congenital Zika syndrome (CZS), severe complications compatible with CZS, or fetal loss. Associations between a laboratory confirmed congenital Zika virus infection and adverse fetal/neonatal outcomes were evaluated. Results Maternal-fetal transmission was documented in 26% (76/291) of fetuses/newborns with complete data. Among the Zika virus positive fetuses/newborns, 45% (34/76) presented with no signs/complications at birth, 20% (15/76) with moderate signs potentially related to CZS, 21% (16/76) with severe complications compatible with CZS, and 14% (11/76) with fetal loss. Compared with the Zika virus positive fetuses/neonates, those that were identified as negative for Zika virus (215/291) were less likely to present with severe complications (5%; 10/215) or fetal loss (0.5%; 1/215; relative risk 6.9, 95% confidence interval 3.6 to 13.3). Association between a positive Zika virus test and any adverse fetal/neonatal outcome was also significant (relative risk 4.4, 2.9 to 6.6). The population attributable fraction estimates that a confirmed congenital Zika virus infection contributes to 47% of adverse outcomes and 61% of severe adverse outcomes observed. Conclusion In cases of a known maternal Zika virus infection, approximately a quarter of fetuses will become congenitally infected, of which a third will have severe complications at birth or fetal loss. The burden of CZS might be lower than initially described in South America and may not differ from other congenital infections.
                Bookmark

                Author and article information

                Contributors
                julien.jaubert@chu-reunion.fr
                laura.atiana@gmail.com
                Sophie.LARRIEU@santepubliquefrance.fr
                philippe.de-vos@cliniquedurieux.fr
                claudine.somon@chu-reunion.fr
                sylvaine.porcherat@chu-reunion.fr
                yoanmb@gmail.com
                florence.naze@chu-reunion.fr
                sandrine.picot@chu-reunion.fr
                malik.boukerrou@chu-reunion.fr
                pierre-yves.robillard@chu-reunion.fr
                patrick.gerardin@chu-reunion.fr
                Journal
                BMC Infect Dis
                BMC Infect. Dis
                BMC Infectious Diseases
                BioMed Central (London )
                1471-2334
                3 April 2020
                3 April 2020
                2020
                : 20
                : 261
                Affiliations
                [1 ]GRID grid.440886.6, ISNI 0000 0004 0594 5118, Laboratoire de Bactériologie, Virologie et Parasitologie, , Centre Hospitalier Universitaire (CHU) de la Réunion, ; Saint Pierre, Reunion France
                [2 ]GRID grid.493975.5, ISNI 0000 0004 5948 8741, CIRE Océan Indien, Santé Publique France, , French National Public Health Agency, ; Saint Denis, Reunion France
                [3 ]Maternité, Clinique Durieux, Le Tampon, Reunion France
                [4 ]GRID grid.440886.6, ISNI 0000 0004 0594 5118, Maternité, Pôle Femme Mère Enfant, , CHU de la Réunion, ; St Pierre, Reunion France
                [5 ]GRID grid.440886.6, ISNI 0000 0004 0594 5118, INSERM CIC 1410 Epidémiologie Clinique, , Centre Hospitalier Universitaire, Groupe Hospitalier Sud Réunion, CHU Réunion, ; BP 350, 97448 Saint Pierre, Cedex-Reunion France
                [6 ]GRID grid.440886.6, ISNI 0000 0004 0594 5118, CEPOI-EA7388, Pôle Femme Mère Enfant, , CHU de la Réunion, ; Saint Pierre, Reunion France
                [7 ]GRID grid.11642.30, ISNI 0000 0001 2111 2608, UM 134 PIMIT Processus Infectieux en Milieu Insulaire Tropical, , Université de La Réunion, ; INSERM 1187, CNRS 9192, IRD 249, CYROI, Sainte Clotilde, Reunion France
                Article
                4969
                10.1186/s12879-020-04969-w
                7118902
                32245372
                f938cb45-7569-490e-98dd-5d2534c2b122
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 18 March 2019
                : 12 March 2020
                Funding
                Funded by: GIRCI SOHO, APIDOM grant 2012
                Award ID: None
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Infectious disease & Microbiology
                immunofluorescence,cross sectional study,q fever,coxiella burnetii,pregnancy,childbirth,parturient woman,prevalence,prevalence proportion ratio,propensity score matching

                Comments

                Comment on this article